Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Etienne Jousseaume"'
Autor:
Gilles Salles, Stephen J. Schuster, Luca Fischer, John Kuruvilla, Piers E. M. Patten, Bastian von Tresckow, Sonali Smith, Ana Jiménez Ubieto, Keith L. Davis, Saurabh Nagar, Jie Zhang, Vamsi Bollu, Etienne Jousseaume, Roberto Ramos, Yucai Wang, Brian K. Link
Publikováno v:
HemaSphere, Vol 6, Iss 7, p e745 (2022)
This study (ReCORD-FL) sought to construct a historical control cohort to augment single-arm trials in relapsed/refractory follicular lymphoma (r/r FL). A retrospective study in 10 centers across North America and Europe was conducted. Adults with gr
Externí odkaz:
https://doaj.org/article/e780703b57a547aa9be64bc3cbede090
Autor:
Nathan H. Fowler, Stephen J. Schuster, Hongbo Yang, Cheryl Xiang, Roberto Ramos, Harald Maier, Carla Anjos, Etienne Jousseaume, Catherine Thieblemont, Martin Dreyling
Publikováno v:
Transplantation and Cellular Therapy. 29:S194
Autor:
Nathan Hale Fowler, Michael Dickinson, Monalisa Ghosh, Andy I. Chen, Charalambos Andreadis, Ranjan Tiwari, Aisha Masood, Roberto Ramos, Etienne Jousseaume, Catherine Thieblemont, Martin Dreyling, Stephen J. Schuster
Publikováno v:
Transplantation and Cellular Therapy. 29:60.e1-60.e4
Follicular lymphoma (FL) is generally considered an indolent disease, although patients with relapsing FL experience progressively shorter durations of response to second or later lines of therapy. The ongoing ELARA trial in adult patients with relap
Autor:
Nathan H. Fowler, Michael Dickinson, Monalisa Ghosh, Andy I. Chen, Charalambos Andreadis, Ranjan Tiwari, Aisha Masood, Roberto Ramos, Vamsi Bollu, Etienne Jousseaume, Catherine Thieblemont, Martin Dreyling, Stephen J. Schuster
Publikováno v:
Transplantation and Cellular Therapy. 28:S170-S171
Autor:
Michael Dickinson, Joaquin Martinez-Lopez, Etienne Jousseaume, Carla Anjos, Hongbo Yang, Xinglei Chai, Cheryl Xiang, Travis Wang, Roberto Ramos, Chiara Lobetti-Bodoni, Stephen J. Schuster, Nathan H. Fowler
Publikováno v:
Transplantation and Cellular Therapy. 28:S65-S66
Autor:
Julie G. Allickson, Rafael G. Amado, Usman Azam, Frank Barry, Irene Aldecoa Bilbao, Gwendolyn K. Binder, Justin L. Black, Karin Blumer, Eugene P. Brandon, David A. Brindley, William Murray Burns, Francesca Capone, Guillaume Carmona, Michael Chaffman, William Chou, Zhanfeng Cui, Kevin A. D’Amour, Nathan J. Dowden, Bernd Eschgfaeller, Eric Faulkner, Maria Cristina Galli, Yoshio Goshima, Stephen J. Haggarty, Celine-Lea Halioua-Haubold, Kristen Harrington-Smith, Darren Hickerson, William Ho, Johan Hyllner, Natasha Iyer, Marieke Jansen, Etienne Jousseaume, Sven Kili, Antoinette F. Konski, Lawrence S. Lamb, Ching Lam, Jaeseung Lim, Chi Lo, Thomas Malcolm, Almudena Martinez-Fernandez, Todd Meinecke, Edward Meinert, Michael C. Milone, David A. Mitchell, Niraj Muni, Filomena Nappi, Neal H. Nathan, Emanuele Ostuni, Marianthi Papakosta, Simona Paratore, Vincenzo Lorenzo Pascali, Cameron D. Pernia, Benjamin Philipson, Fiona Phillips, James B. Phillips, Nasib Qureshi, Pietro Refolo, Moira Ringo, Matthew Robson, Crystal Ruff, Manuel Schmidt, Matthias Schroff, Michael J. Scott, Michaela Sharpe, Richard L. Sidman, John D. Sinden, Devyn M. Smith, Evan Y. Snyder, Sita Somara, Antonio Gioacchino Spagnolo, Daryl S. Spinner, Kanaka Sridharan, Michael Sullivan, Keith Thompson, Brian T.D. Tobe, Alain A. Vertès, Michael D. West, Cynthia Wilkins-Port, Burghardt Wittig, Aidong Yang, Jie Zhang, Mark C. Zimmerman
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::557c2ce10a659280ef90bb6618f8deb1
https://doi.org/10.1016/b978-0-12-812034-7.01002-5
https://doi.org/10.1016/b978-0-12-812034-7.01002-5
Autor:
Fiona Phillips, Etienne Jousseaume, Kristen Harrington-Smith, Emanuele Ostuni, Karin Blumer, Simona Paratore, Bernd Eschgfaeller, Marieke Jansen, Irene Aldecoa Bilbao, Jie Zhang, Matthew Robson, William Chou
In August 2017, the FDA approved the first–ever chimeric antigen receptor T cell (CAR–T) therapy for the use in terminally ill paediatric leukaemia patients. Today, this therapy, which genetically modifies a patient’s own immune cells to enable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::573ab29e200ab8b8d1288e34a82cafd7
https://doi.org/10.1016/b978-0-12-812034-7.00028-5
https://doi.org/10.1016/b978-0-12-812034-7.00028-5
Autor:
Monalisa Ghosh, Ranjan Tiwari, Catherine Thieblemont, Andy I. Chen, Roberto Ramos, Vamsi Bollu, Etienne Jousseaume, Martin Dreyling, Michael Dickinson, Stephen J. Schuster, Charalambos Andreadis, Aisha Masood, Nathan Fowler
Publikováno v:
Blood. 138:3533-3533
Background: Follicular lymphoma (FL) is the second most frequently diagnosed Non-Hodgkin lymphoma subtype in Western countries. Patients often undergo multiple lines of therapy over many years throughout the course of their disease with worse surviva
Autor:
Bastian von Tresckow, Keith L. Davis, Saurabh P Nagar, Ana Isabel Jiminez Ubieto, Vamsi Bollu, Sonali M. Smith, Etienne Jousseaume, Yucai Wang, John Kuruvilla, Brian K. Link, Luca Fischer, Stephen J. Schuster, Gilles Salles, Jie Zhang, Roberto Ramos, Piers Em Patten
Publikováno v:
Blood. 138:1349-1349
Background: Novel therapies for multiply relapsed follicular lymphoma (FL) are often evaluated in single arm trials with no comparative data on patients receiving usual care. This study (ReCORD-FL) therefore sought to construct a historical control c
Publikováno v:
Blood. 138:1360-1360
Objective: To determine treatment regimens used in clinical practice and the associated clinical outcomes among third line (3L) follicular lymphoma (FL) patients in the United States (US). Methods: This non-interventional, retrospective study used Op